^
    Back
    Association details:
    Biomarker:CD14 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

    Published date:
    11/01/2018
    Excerpt:
    To identify biomarkers associated with venetoclax sensitivity, we developed an integrative Bayesian machine learning method that jointly modeled both data sets, revealing several candidate biomarkers positively (BCL2 and FLT3) or negatively (CD14, MAFB, and LRP1) correlated with venetoclax response.
    DOI:
    10.1182/blood-2018-99-111916
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

    Published date:
    11/01/2018
    Excerpt:
    AML patient samples expressing CD14 detected by flow cytometry also demonstrated reduced venetoclax sensitivity (p=0.005), which could potentially serve as a biomarker to identify venetoclax resistant patients.
    DOI:
    https://doi.org/10.1182/blood-2018-175